The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Romanov D.V.

Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center

Samsonova M.D.

Sechenov First Moscow State Medical University (Sechenov University)

Yuzbashyan P.G.

Sechenov First Moscow State Medical University (Sechenov University)

Treatment of mental disorders caused or triggered by somatic and neurological diseases with the use of the multimodal antidepressant trazodone

Authors:

Romanov D.V., Samsonova M.D., Yuzbashyan P.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(4‑2): 81‑89

DOI: 10.17116/jnevro202312304281

Read: 8511 times

Download PDF (RU)
Contact the author
Table of contents

TREATMENT OF MENTAL DISORDERS CAUSED OR TRIGGERED BY SOMATIC AND NEUROLOGICAL DISEASES WITH THE USE OF THE MULTIMODAL ANTIDEPRESSANT TRAZODONE
TREATMENT OF MENTAL DISORDERS CAUSED OR TRIGGERED BY SOMATIC AND NEUROLOGICAL DISEASES WITH THE USE OF THE MULTIMODAL ANTIDEPRESSANT TRAZODONE

To cite this article:

Romanov DV, Samsonova MD, Yuzbashyan PG. Treatment of mental disorders caused or triggered by somatic and neurological diseases with the use of the multimodal antidepressant trazodone. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(4‑2):81‑89. (In Russ.)
https://doi.org/10.17116/jnevro202312304281

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Asthenia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):5-10
Pathogenetic inte­rrelations of hypo­gonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23
Nutritional care for patients with neurodegenerative diseases in the outpatient practice of a neurologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):76-83
Acute postoperative pain in pediatric neurosurgery: state of the problem and effe­ctiveness of modern pain relief methods. Russian Journal of Anesthesiology and Reanimatology. 2025;(1):30-35
A personalized approach to the treatment of chro­nic tension headache and como­rbid mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):51-57
Expe­rience with the use of amitriptyline for chro­nic pelvic pain asso­ciated with endo­metriosis. Russian Journal of Human Reproduction. 2025;(1):86-93
Prevention and treatment of post-thoracotomy pain syndrome from the perspective of thoracic surgeon. Russian Journal of Pain. 2025;(1):62-68
Sleep deprivation and the deve­lopment of oxidative stress in animal models. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):124-129
Prediction and prevention of burnout syndrome in health care professionals in high epidemic risk settings. Russian Journal of Preventive Medi­cine. 2025;(4):51-56
Obje­ctification of Pain in Patients with Endo­metriosis. (Literature review and own data). Russian Journal of Human Reproduction. 2025;(2):62-85
Abstract:

The purpose of this narrative review is to relate current data on the molecular mechanisms of action of trazodone with its clinical effects and applicability in mental disorders caused or triggered by somatic and neurological disease, according to available publications. In the article, the prospects for the use of the multimodal antidepressant trazodone are discussed in accordance with therapeutic targets. The latter are discussed in accordance with the typology of the mentioned above psychosomatic disorders. Trazodone is an antidepressant acting primarily due to the blockade of postsynaptic serotonin 5H2A- and 5H2C-receptors, as well as the blockade of serotonin reuptake, but also has affinity for a number of additional receptors. The drug has a favorable safety profile and a wide range of beneficial effects: antidepressive, somnolent, anxiolytic, anti-dysphoric and somatotropic. This makes it possible to influence a wide range of therapeutic targets in the structure of mental disorders caused or triggered by somatic and neurological diseases, carrying out safe and effective psychopharmacotherapy.

Keywords:

psychosomatic disorders
depression
insomnia
anxiety
dysphoria
aggression
pain
sexual dysfunction
multimodal antidepressants
5HT2A
5HT2C
trazodone

Authors:

Romanov D.V.

Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center

Samsonova M.D.

Sechenov First Moscow State Medical University (Sechenov University)

Yuzbashyan P.G.

Sechenov First Moscow State Medical University (Sechenov University)

Received:

15.02.2023

Accepted:

15.03.2023

Close metadata

References:

  1. Smulevich AB. Psihosomaticheskie rasstrojstva v klinicheskoj praktike. Pod red. akad. RAN Smulevicha A.B. 2-e izd. M.: MEDpress-inform; 2019;776. (In Russ.).
  2. Rasstrojstva psihosomaticheskogo spektra: patogenez, diagnostika, lechenie: rukovodstvo dlya vrachej. Pod red. Storozhakova G.I., Shamreya V.K. SPb.: SpecLit; 2014;303. (In Russ.).
  3. Smulevich AB. Psihopatologiya lichnosti i komorbidnyh rasstrojstv. M.: MEDpress-Inform; 2009;208. (In Russ.).
  4. Psihiatriya: Kratkoe izdanie: nacional’noe rukovodstvo. Yu.A. Aleksandrovskij, V.V. Vandysh-Bubko, A.V. Vasil’eva i dr. 2-e izdanie, pererabotannoe i dopolnennoe. Moskva: Obshchestvo s ogranichennoj otvetstvennost’yu Izdatel’skaya gruppa «GEOTAR-Media»; 2021;768. (In Russ.).
  5. Smulevich AB, Dubnitskaia ÉB. A dimensional rhythmological model of depression. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2010;110(1):4-10. (In Russ.).
  6. Greenfield DP. Psychopharmacology for Nonpsychiatrists: A Primer. Springer International Publishing; 2022. https://doi.org/10.1007/978-3-030-82507-2
  7. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge University Press; 2021. https://doi.org/10.1017/9781108975292
  8. Danilov DS. Multimodal serotonergic antidepressants. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(9):103-111. (In Russ.). https://doi.org/10.17116/jnevro201711791103-111
  9. Oggianu L, Di Dato G, Mangano G, et al. Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations. Clin Transl Sci. 2022;15(6):1417-1429. https://doi.org/10.1111/cts.13253
  10. Segelcke D, Messlinger K. Putative role of 5-HT2B receptors in migraine pathophysiology. Cephalalgia. 2017;37(4):365-371.  https://doi.org/10.1177/0333102416646760
  11. Marek GJ, McDougle CJ, Price LH, Seiden LS. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11.  https://doi.org/10.1007/BF02245475
  12. Settimo L, Taylor D. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets. J Psychopharmacol. 2018;32(1):96-104.  https://doi.org/10.1177/0269881117742101
  13. Papakostas GI, Fava MA. Meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry. 2007;22(7):444-447. 
  14. Khouzam HR. A review of trazodone use in psychiatric and medical conditions. Postgrad Med. 2017;129(1):140-148. Epub 2016 Oct 28.  https://doi.org/10.1080/00325481.2017.1249265
  15. Salzman C. Pharmacologic treatment of depression in the elderly. J Clin Psychiatry. 1993;54(suppl):23-28. 
  16. Nierenberg AA, Cole JO, Glass L. Possible trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry. 1992;53(3):83-85. 
  17. Jaffer KY, Chang T, Vanle B, et al. Trazodone for Insomnia: A Systematic Review. Innov Clin Neurosci. 2017;14(7-8):24-34. 
  18. Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. 2011;20(4):552-558.  https://doi.org/10.1111/j.1365-2869.2011.00928.x
  19. Zheng Y, Lv T, Wu J, Lyu Y. Trazodone changed the polysomnographic sleep architecture in insomnia disorder: a systematic review and meta-analysis. Sci Rep. 2022;12(1):14453. https://doi.org/10.1038/s41598-022-18776-7
  20. Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry. 1990;51(suppl):13-17. 
  21. Maher MJ, Rego SA, Asnis GM. Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. CNS Drugs. 2006;20(7):567-590.  https://doi.org/10.2165/00023210-200620070-00003
  22. Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151(7):1069-1072. https://doi.org/10.1176/ajp.151.7.1069
  23. Wang J, Liu S, Zhao C, et al. Effects of Trazodone on Sleep Quality and Cognitive Function in Arteriosclerotic Cerebral Small Vessel Disease Comorbid With Chronic Insomnia. Front Psychiatry. 2020;11:620.  https://doi.org/10.3389/fpsyt.2020.00620
  24. Camargos EF, Pandolfi MB, Freitas MP, et al. Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study. Arq Neuropsiquiatr. 2011;69(1):44-49.  https://doi.org/10.1590/s0004-282x2011000100010
  25. Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. Journal Psychopharmacology. 2005;19(3):235-241.  https://doi.org/10.1177/0269881105051526
  26. Mittur A. Trazodone: properties and utility in multiple disorders. Expert Rev Clin Pharmacol. 2011;4(2):181-196.  https://doi.org/10.1586/ecp.10.138
  27. Mavissakalian M, Perel J, Bowler K, Dealy R. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry. 1987;144(6):785-787.  https://doi.org/10.1176/ajp.144.6.785
  28. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50(11):884-895.  https://doi.org/10.1001/archpsyc.1993.01820230054005
  29. Peeters DGA, de Boer SF, Terneusen A, et al. Enhanced aggressive phenotype of Tph2 knockout rats is associated with diminished 5-HT1A receptor sensitivity. Neuropharmacology. 2019;153:134-141.  https://doi.org/10.1016/j.neuropharm.2019.05.004
  30. de Boer SF, Newman-Tancredi A. Anti-aggressive effects of the selective high-efficacy ‘biased’ 5-HT₁A receptor agonists F15599 and F13714 in male WTG rats. Psychopharmacology (Berl). 2016;233(6):937-947.  https://doi.org/10.1007/s00213-015-4173-x
  31. Kitamura Y, Kudo Y, Imamura T. Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer’s disease: a retrospective study focused on the aggression and negativism in caregiving situations. No To Shinkei. 2006;58(6):483-488. (Japanese).
  32. Lopez-Pousa S, Garre-Olmo J, Vilalta-Franch J, et al. Trazodone for Alzheimer’s disease: a naturalistic follow-up study. Arch Gerontol Geriatr. 2008;47(2):207-215. 
  33. Davies SJ, Burhan AM, Kim D, et al. Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia. J Psychopharmacol. 2018;32(5):509-523. 
  34. Ringman JM, Schneider L. Treatment Options for Agitation in Dementia. Curr Treat Options Neurol. 2019;21(7):30.  https://doi.org/10.1007/s11940-019-0572-3
  35. Mashiko H, Yokoyama H, Matsumoto H, Niwa S. Trazodone for aggression in an adolescent with hydrocephalus. Psychiatry Clin Neurosci. 1996;50(3):133-136.  https://doi.org/10.1111/j.1440-1819.1996.tb01677.x
  36. Ghaziuddin N, Alessi NE. An open clinical trial of trazodone in aggressive children. J Child Adolesc Psychopharmacol. 1992;2(4):291-297.  https://doi.org/10.1089/cap.1992.2.291
  37. Zubieta JK, Alessi NE. Acute and chronic administration of trazodone in the treatment of disruptive behavior disorders in children. J Clin Psychopharmacol. 1992;12(5):346-351. 
  38. Ghaziuddin N, Alessi NE. An open clinical trial of trazodone in aggressive children. J Child Adolesc Psychopharmacol. 1992;2(4):291-297.  https://doi.org/10.1089/cap.1992.2.291
  39. Khurana RC. Treatment of painful diabetic neuropathy with trazodone. JAMA. 1983;250(11):1392. https://doi.org/10.1001/jama.1983.03340110016015
  40. Wilson RC. The use of low-dose trazodone in the treatment of painful diabetic neuropathy. J Am Podiatr Med Assoc. 1999;89(9):468-471.  https://doi.org/10.7547/87507315-89-9-468
  41. Battistella PA, Ruffilli R, Cernetti R, et al. A placebo-controlled crossover trial using trazodone in pediatric migraine. Headache. 1993;33(1):36-39.  https://doi.org/10.1111/j.1526-4610.1993.hed3301036.x
  42. Paolucci M, Altamura C, Vernieri F. The Role of Endothelial Dysfunction in the Pathophysiology and Cerebrovascular Effects of Migraine: A Narrative Review. J Clin Neurol. 2021;17(2):164-175.  https://doi.org/10.3988/jcn.2021.17.2.164
  43. Fink HA, MacDonald R, Rutks IR, Wilt TJ. Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU International. 2003;92(4):441-446.  https://doi.org/10.1046/j.1464-410x.2003.04358.x
  44. Agnoli A, De Gregorio M, Dionisio A. Trazodone, a review of clinical literature and personal experience. Psychopathology. 1984;17(suppl 2):88-103. 
  45. Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994;4(4):331-355.  https://doi.org/10.2165/00002512-199404040-00006
  46. Burgess CD, Hames TK, George CF. The electrocardiographic and anticholinergic effects of trazodone and imipramine in man. Eur J Clin Pharmacol. 1982;23(5):417-421. 
  47. Calvi A, Fischetti I, Verzicco I, et al. Antidepressant Drugs Effects on Blood Pressure. Front Cardiovasc Med. 2021;8:704281. https://doi.org/10.3389/fcvm.2021.704281
  48. Fagiolini A, Comandini A, Dell’Osso MC, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033-1049. https://doi.org/10.1007/s40263-012-0010-5
  49. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. Pragma Pharmaceuticals (2017). Prescribing information for trazodone hydrochloride. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018207s032lbl.pdf.
  50. Bossini L, Casolaro I, Koukouna D, et al. Off-label uses of trazodone: a review. Expert Opin Pharmacother. 2012;13(12):1707-1717. https://doi.org/10.1517/14656566.2012.699523
  51. Kellams JJ, Klapper MH, Small JG. Trazodone, a new antidepressant: efficacy and safety in endogenous depression. J Clin Psychiatry. 1979;40(9):390-395. 
  52. Fagiolini A, Albert U, Ferrando L, et al. A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. Int Clin Psychopharmacol. 2020;35(3):137-146.  https://doi.org/10.1097/YIC.0000000000000304
  53. Kasper S, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin. 2005;21(8):1139-1146. https://doi.org/10.1185/030079905X53243
  54. Beasley CM Jr, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry. 1991;52(7):294-299. 
  55. Munizza C, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin. 2006;22(9):1703-1713. https://doi.org/10.1185/030079906X121039
  56. Maresh S, Prowting J, Vaughan S, et al. Buspirone decreases susceptibility to hypocapnic central sleep apnea in chronic SCI patients. J Appl Physiol (1985). 2020;129(4):675-682.  https://doi.org/10.1152/japplphysiol.00435.2020
  57. Buoli M, Rovera C, Pozzoli SM, et al. Is trazodone more effective than clomipramine in major depressed outpatients? A single-blind study with intravenous and oral administration. CNS Spectr. 2019;24(2):258-264.  https://doi.org/10.1017/S1092852917000773
  58. Altamura AC, Mauri MC, Rudas N, et al. Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: a controlled multicenter trial. Clin Neuropharmacol. 1989;12(suppl 1):25-33; 34-37.  https://doi.org/10.1097/00002826-198901001-00005
  59. Savarese M, Carnicelli M, Cardinali V, et al. Subjective hypnotic efficacy of Trazodone and Mirtazapine in patients with chronic insomnia: a retrospective, comparative study. Arch Ital Biol. 2015;153(2-3):231-238.  https://doi.org/10.12871/0003982920152348
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.